Tariff hikes and a reduction in competitive intensity in customer acquisitions will also be key to ensure a sustained revival, Motilal Oswal wrote in its note, adding that the latter two factors are not entirely in the company’s control as…
Gold ETFs are drawing record inflows both in India and globally as investors look to hedge against rising debt and economic uncertainty. Vikram Dhawan says while the long-term fundamentals for gold and silver remain strong, the road ahead will be…
US equities stalled as Nvidia Corp. fell after SoftBank Group Corp. sold its stake, CoreWeave Inc. dropped on a revenue cut, and traders eyed weak labor data and rising bearish bets on Nasdaq.
SafeGold CEO Gaurav Mathur believes India’s vast household gold reserves can be transformed into a source of global capital if the government introduces clear rules for retail gold leasing. He said a regulatory framework would not only safeguard consumers but…
Several major companies announced their Q2 results, reflecting a mixed performance across sectors. Tata Power, RVNL, and Max Financial Services saw profit declines, while Torrent Power, Gujarat Fluorochemicals, and Pearl Global posted strong growth. CONCOR declared an interim dividend, PI…
Biocon Ltd reported Q2 FY26 revenue of ₹4,296 crore, up nearly 20% YoY, led by strong biosimilars performance and improving margins across global markets.
Record date for the rights issue has been fixed as November 17, 2025. Those shareholders who have shares of Adani Enterprises as of Friday, November 14, will be eligible to subscribe to the rights issue.
Pine Labs’ ₹3,900 crore IPO was subscribed 2.5 times, driven by strong institutional interest but tepid retail demand amid valuation and profitability concerns.
Pearl Global Industries reported a 25.5% YoY rise in Q2 FY26 profit to ₹73.3 crore, supported by strong growth in Vietnam and Indonesia. The company declared a ₹6 interim dividend and announced a ₹250 crore capex plan for expansion and…
JB Pharma reported a 19% net profit rise to ₹207.8 crore, driven by strong domestic sales of Cilacar, Metrogyl, Nicardia, Sporlac, and Razel, with international revenue up 7%. The shares of JB Pharma ended 0.7% in the green on Tuesday,…